Neogen Chemicals Q1 FY27 Earnings Call — Analysis (NSE: NEOGEN)

Neogen Chemicals delivers strong Q1FY27 with revenue up 34% YoY to ₹250 Cr and raises standalone guidance to ₹950–1,050 Cr on the back of organo-lithium and battery chemicals momentum.

1 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue ₹250 Cr ( +34% YoY ) . New guidance — FY27 base business (legacy chemicals… ₹950 to ₹1,050 Cr . New story: Battery chemicals becoming major revenue driver .

Results

Q1FY27 consolidated revenue ₹250 Cr (+34% YoY); EBITDA ₹48.2 Cr (+53% YoY) with margin 19.3% (+260bps); PAT ₹17.1 Cr (+67% YoY).

Financial highlights

Guidance

Standalone revenue guidance raised to ₹950–1,050 Cr; battery chemicals FY27 revenue maintained at ~₹300 Cr (₹200 Cr salts, ₹100 Cr electrolytes) with H2 ramp-up.

What management committed to

• Management has revised the standalone (base business) revenue guidance for FY27 to ₹950–1,050 Cr, up from the earlier range of ₹875–950 Cr. — ₹950 to ₹1,050 Cr, FY27
• Battery chemicals (Neogen Ionics) revenue is expected to be ~₹300 Cr in FY27, with approximately ₹200 Cr from electrolyte salts and ₹100 Cr from electrolytes. — ₹300 Cr, FY27
• Electrolyte salt capacity is expected to reach 70–80% utilisation in FY28. — 70-80%, FY28
• The battery chemicals business at full capacity is expected to generate ₹2,400–2,900 Cr in revenue by FY29. — ₹2,400 to ₹2,900 Cr, FY29
• Base business EBITDA margin is expected to be 18% ±1–1.5% in FY27 (i.e., 16.5–19.5%). — 18% plus-minus 1-1.5%, FY27
• Base business EBITDA margin in FY28 is targeted at 18–20% (18% plus, hopefully not minus, or 19% ±1%). — 18-20%, FY28
• Battery business is expected to deliver a 20% ROCE on full utilisation by FY29. — 20%, FY29
• Commercial production at the Dahej replacement plant will commence in Q2 FY27. — Q2FY27
• Electrolyte plant commissioning (commercial production) is targeted for H1 FY27 (by September 2026). — H1FY27
• Lithium electrolyte salts plant commissioning is targeted for H2 FY27 (by March 2027). — H2FY27
• The proposed QIP of ₹600 Cr will primarily be used for debt reduction; post-QIP peak consolidated net debt is expected to be ₹1,000–1,500 Cr, down from ~₹1,800 Cr. — ₹1,000-1,500 Cr, FY27
• Base business working capital cycle is targeted at 140–150 days by FY28. — 140-150 days, FY28

Key themes

Battery chemicals ramp-up and balance sheet deleveraging

How the narrative shifted

• Battery chemicals becoming major revenue driver: Management positions Neogen Ionics as a giga-scale, non-China electrolyte and salt supplier set to capture a 236 GWh addressable market by 2032, with FY27 as the inflection year.
• Standalone business guidance upgrade signals resilience: The upgraded FY27 revenue guidance to ₹950–1,050 Cr reflects organo-lithium capacity hitting full utilisation and sustained organic chemical demand, reinforcing confidence in the core portfolio.
• Balance sheet deleveraging via QIP: The planned ₹600 Cr QIP is framed as a pre-emptive move to reduce debt and create dry powder for future battery and organo-lithium growth, lowering financial risk before the next capex cycle.
• Dahej replacement plant recovery: The near-complete rebuild of the Dahej facility (commercial production Q2FY27) removes a key operational overhang and sets the stage for CSM and agro recovery.
• Global non-FEOC supply chain shift: Customers are accelerating transition to non-China electrolyte supply to comply with US 45X tax credits by 2027, creating a large, policy-driven demand pull for Neogen’s Japanese-tech-based salts and electrolytes.
• Organo-lithium expansion cycle: Organo-lithium hit full capacity in Q1; further brownfield expansion is likely to be approved in H2FY27, supporting additional volume growth in pharma, semiconductors and agro.
• Working capital and cash flow normalisation: Management acknowledges elevated working capital due to fire disruption and product complexity, but articulates a clear playbook to bring base business to 140-150 days by FY28, while battery business runs at ~90 days.

Operational commentary

• Neogen Ionics battery chemicals revenue surged to ₹19 Cr in Q1FY27 (vs ₹5 Cr Q1FY26), driven by electrolyte salt sales; plant commissioning on track – electrolyte H1FY27, salts H2FY27.
• Dahej replacement plant nearing completion with trial runs underway; commercial production expected in Q2FY27, restoring flagship CSM capacity.
• Organo-lithium capacity reached full utilisation in Q1, driving highest-ever quarterly revenue in that vertical; further capacity increase to be evaluated by end-Q2FY27.
• Four international electrolyte manufacturer audits completed and provisional approvals secured for lithium electrolyte salts; commercial supplies post final plant trial approvals.
• Proposed QIP of ₹600 Cr approved by board to reduce debt and create headroom for future growth in battery materials and organo-lithium.
• Morita’s USD 20 million equity contribution expected in Q2–Q3FY27, funding the battery joint venture’s final capex.
• Government ACC PLI re-bidding for 10 GWh and proposed PLI scheme for battery components to support domestic cell manufacturing and raw material localisation.

Analyst Q&A

• Q. What are the contours of the government’s proposed battery component PLI scheme and potential benefits for Neogen?

  The PLI scheme is still under discussion and not yet finalized; the intent is to support localisation of battery cell production and level the playing field against Chinese competition. We will share details once the scheme is published.

• Q. When can we expect operating cash flow conversion consistently above 70% of EBITDA?

  The base business working capital will improve to 140-150 days by FY28 as we move to larger molecules; battery business targets 90 days. FY29 should see an optimised business with strong cash conversion, but consistent positive operating cash flow cannot be promised while the company is growing.

View source

Research and educational content only. Not investment advice.